FIELD: medicine. SUBSTANCE: invention relates to the developed recombinant immunotoxin based on DIPHTHERITIC toxin and interleukin-2 where catalytic-transmembrane moiety of diphtheric toxin contains 482 amino acids. Invention proposes also a method of preparing recombinant immunotoxin DT482-IL2. New immunotoxin can be used for making drug used for treatment of tumor and autoimmune diseases. Method provides high protein toxicity and capability to secret into extracellular space. EFFECT: enhanced effectiveness and properties of immunotoxin. 2 cl, 3 dwg
Authors
Dates
1998-07-20—Published
1997-07-22—Filed